The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called nivolumab in patients with stage IIIB or IV squamous cell lung cancer that has continued to grow despite at least two prior regimens of chemotherapy.
Nivolumab boosts the body’s immune system by targeting a protein on white blood cells called PD-1. PD-1 normally maintains the balance of the immune system by shutting it down at the right time. Some cancers take advantage of this shut-down mechanism by activating PD-1, enabling them to escape attack by the body’s white blood cells. Nivolumab binds to and inactivates PD-1, enhancing the body’s ability to detect and destroy cancer cells.